Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pacira Pharma (PCRX) Tops Q2 EPS by 6c, Revenues Beat; Provides FY19 Sales Outlook
August 8, 2019 8:04 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $102.6 million versus the consensus estimate of $100.45 million.
Second Quarter 2019 Financial Results
Total revenues were $102.6 million in the second quarter of 2019, a 22 percent increase over the $84.1 million reported for the second quarter of 2018.Total net product sales were $101.8 million in the second quarter of 2019, a 26 percent increase over the $80.7 million reported for the second quarter of 2018.Net product sales of EXPAREL/bupivacaine liposome injectable suspension were $99.8 million in the second... More